Exelixis, Inc. Drug Shows Promise in Brain Cancer-Study

Reuters -- An experimental drug being developed by Exelixis Inc and Bristol-Myers Squibb Co was shown to shrink brain tumors in some patients, according to interim results from a mid-stage study of the drug, known as XL184.